VRTX and REGN Related Headlines
Go Back- 4Q25/2026 Biotech Earnings Preview: RBC
- Bernstein's US Biotech 3Q25 Preview: 'Expect Beats from ALNY and REGN'
- Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
- FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
